Professional Summary
Professional Overview
Yangde Chen is an accomplished biopharmaceutical executive with extensive expertise in innovative biologics development and commercialization. As the Co-Founder, CTO/COO of MLAB Biosciences, he leads the company's technical and operational strategy, driving the advancement of cutting-edge biotherapeutics.
Experience Summary
Current Role
As the Co-Founder, CTO/COO of MLAB Biosciences, Yangde Chen is responsible for overseeing the company's technical roadmap and operational excellence. He leverages his deep industry knowledge and proven track record to guide the development and commercialization of MLAB's proprietary biotherapeutic platforms, with a focus on addressing unmet medical needs.
Career Progression
Prior to co-founding MLAB Biosciences, Yangde Chen held leadership positions at various prominent biopharmaceutical companies. As an Entrepreneur in Residence at ABio-X, he provided strategic guidance and advisory services to advance innovative biotechnology initiatives. He also served as a Biologics Adviser at OnCusp Therapeutics, contributing his expertise in the development of next-generation biotherapeutics.
Yangde's extensive industry experience includes serving as the VP of Innovative Biologics at Klus Pharma, where he led the company's efforts in the discovery and development of novel biological drugs. He also held the role of VP and Head of Antibody Discovery at Abpro, driving the advancement of their antibody-based therapeutics.
Earlier in his career, Yangde held various research and development positions at Sanofi, progressing from Principal Research Investigator to Director and Associate Director, where he made significant contributions to the company's biologics pipeline.
Academic Background
Yangde Chen holds a Ph.D. in Biochemistry and Molecular Biology, which has provided him with a strong foundation in the scientific principles underlying biotherapeutic development.
Areas of Expertise
- Innovative biologics development and commercialization
- Antibody discovery and engineering
- Biotherapeutic platform technology advancement
- Cross-functional team leadership and collaboration
- Strategic planning and operational excellence
Professional Impact
Yangde Chen's extensive industry experience and technical expertise have resulted in numerous achievements, including the successful development and advancement of biotherapeutic candidates, the establishment of productive industry partnerships, and the implementation of operational best practices. His contributions have been instrumental in driving the growth and success of the organizations he has been affiliated with.
Conclusion
Yangde Chen's diverse background and proven track record in the biopharmaceutical industry make him a valuable asset to MLAB Biosciences. As the Co-Founder, CTO/COO, he is poised to lead the company's technical and operational strategies, leveraging his expertise to accelerate the development and commercialization of innovative biotherapeutics that can positively impact patient outcomes.
